Leerink Partnrs Has Bullish Outlook for RXRX Q3 Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Equities research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Recursion Pharmaceuticals in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.24) per share for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($0.81) EPS and FY2027 earnings at ($0.36) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The company’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) EPS.

RXRX has been the topic of a number of other research reports. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.00.

Recursion Pharmaceuticals Trading Down 0.9%

Shares of RXRX opened at $5.36 on Friday. The stock’s 50-day moving average is $5.40 and its two-hundred day moving average is $5.91. The stock has a market cap of $2.18 billion, a PE ratio of -3.01 and a beta of 0.93. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 4.11.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc lifted its stake in shares of Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after acquiring an additional 1,300 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after buying an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC increased its holdings in Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock valued at $113,000 after buying an additional 1,907 shares during the last quarter. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after buying an additional 2,026 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Recursion Pharmaceuticals by 16.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock valued at $78,000 after buying an additional 2,219 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.